New Antibody-Drug conjugate enters human trials for Hard-to-Treat cancers

NCT ID NCT07362888

Recruiting now Disease control Sponsor: Adcendo ApS Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 24, 2026 · Updated 5 times

Summary

This early-stage trial is testing a new drug called ADCE-B05 in 180 people with advanced solid tumors that have not responded to standard treatments. The drug is an antibody-drug conjugate, designed to deliver a cancer-killing agent directly to tumor cells. The main goals are to find the safest dose and check for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ADCE-B05 (an antibody-drug conjugate)
What this could lead to: If successful, this could point toward a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong: This is a very early Phase 1 trial focused on safety and dosing, not yet on effectiveness. The drug may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMORS (PHASE 1)

Contacts and locations

Locations

Highlands Oncology Group
RECRUITING

Springdale, Arkansas, 72762, United States
Monash Health
RECRUITING

Clayton, Victoria, 3165, Australia
Peter MacCallum Cancer Centre
RECRUITING

Melbourne, Victoria, 3000, Australia
Scientia Clinical Research
RECRUITING

Randwick, New South Wales, 2031, Australia
Southern Oncology Clinical Research Unit
RECRUITING

Bedford Park, South Australia, 5042, Australia
University Of Texas MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
Yale University
RECRUITING

New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.